0.7962
1.46%
-0.0118
Pre-market:
.78
-0.0162
-2.03%
Aptevo Therapeutics Inc stock is currently priced at $0.7962, with a 24-hour trading volume of 159.11K.
It has seen a -1.46% decreased in the last 24 hours and a +3.67% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8129 pivot point. If it approaches the $0.7852 support level, significant changes may occur.
Previous Close:
$0.808
Open:
$0.8224
24h Volume:
159.11K
Market Cap:
$3.25M
Revenue:
$12.99M
Net Income/Loss:
$-17.41M
P/E Ratio:
-0.242
EPS:
-3.29
Net Cash Flow:
$-11.73M
1W Performance:
-14.84%
1M Performance:
+3.67%
6M Performance:
+337.47%
1Y Performance:
-50.24%
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206 838 0500
Address
2401 4th Avenue, Suite 1050, Seattle, WA
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA - Yahoo Finance
Yahoo Finance
Views of Wall Street's Leading Experts on Aptevo Therapeutics Inc – Sete News - SETE News
SETE News
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update - 08.05.2024 - wallstreet:online
wallstreet:online
Get in on Aptevo Therapeutics Inc's (APVO) buy-in window today! – Sete News - SETE News
SETE News
Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket - Aptevo Therape - Benzinga
Benzinga
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Zacks Investment Research
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Aptevo Therapeutics Inc (APVO) Revenue 2024
APVO reported a revenue (TTM) of $12.98 million for the quarter ending March 31, 2022.
Aptevo Therapeutics Inc (APVO) Net Income 2024
APVO net income (TTM) was -$17.41 million for the quarter ending December 31, 2023, a -316.92% decrease year-over-year.
Aptevo Therapeutics Inc (APVO) Cash Flow 2024
APVO recorded a free cash flow (TTM) of -$11.73 million for the quarter ending December 31, 2023, a +44.28% increase year-over-year.
Aptevo Therapeutics Inc (APVO) Earnings per Share 2024
APVO earnings per share (TTM) was -$72.30 for the quarter ending December 31, 2023, a -204.00% decline year-over-year.
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Cap:
|
Volume (24h):